|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0032743,
umls-concept:C0087111,
umls-concept:C0152013,
umls-concept:C0205179,
umls-concept:C0681842,
umls-concept:C0871261,
umls-concept:C1122962,
umls-concept:C1547085,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
22
|
|
pubmed:dateCreated |
2008-11-17
|
|
pubmed:abstractText |
To evaluate the usefulness of 3'-deoxy-3'-[18F]fluorothymidine (FLT)-positron emission tomography (PET) for predicting response and patient outcome of gefitinib therapy in patients with adenocarcinoma of the lung.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
7423-9
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19010859-Adenocarcinoma,
pubmed-meshheading:19010859-Adult,
pubmed-meshheading:19010859-Aged,
pubmed-meshheading:19010859-Aged, 80 and over,
pubmed-meshheading:19010859-Antineoplastic Agents,
pubmed-meshheading:19010859-Female,
pubmed-meshheading:19010859-Fluorine Radioisotopes,
pubmed-meshheading:19010859-Humans,
pubmed-meshheading:19010859-Kaplan-Meier Estimate,
pubmed-meshheading:19010859-Lung Neoplasms,
pubmed-meshheading:19010859-Male,
pubmed-meshheading:19010859-Middle Aged,
pubmed-meshheading:19010859-Neoplasm Recurrence, Local,
pubmed-meshheading:19010859-Positron-Emission Tomography,
pubmed-meshheading:19010859-Prognosis,
pubmed-meshheading:19010859-Quinazolines,
pubmed-meshheading:19010859-ROC Curve,
pubmed-meshheading:19010859-Radiopharmaceuticals,
pubmed-meshheading:19010859-Thymidine,
pubmed-meshheading:19010859-Time,
pubmed-meshheading:19010859-Tomography, X-Ray Computed
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
[18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung.
|
|
pubmed:affiliation |
Division of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
